On Thursday, Maze Therapeutics experienced a significant surge in its stock value after its potential treatment for a rare genetic disorder far exceeded the company's initial projections. The therapy recorded a remarkable 51% increase, showcasing its promising outcome. This unforeseen success has astonished Maze Therapeutics, prompting optimism and interest in its future developments.